Agents interfering with the renin-angiotensin system (RAS) consistently lower the incidence of type 2 diabetes mellitus compared to other antihypertensive drugs in hypertensive high-risk populations.
Do agents interfering with the renin-angiotensin system reduce the incidence of type 2 diabetes mellitus in hypertensive high-risk populations?
This review highlights that RAS blockade using ACE inhibitors or ARBs may protect against the development of type 2 diabetes in high-risk hypertensive patients by improving beta-cell function and insulin sensitivity.
Agents interfering with the renin-angiotensin system (RAS) were consistently shown to lower the incidence of type 2 diabetes mellitus (T2DM), as compared to other antihypertensive drugs, in hypertensive high-risk populations. The mechanisms underlying this protective effect of RAS blockade using angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on glucose metabolism are not fully understood. In this article, we will review the evidence from randomized controlled trials and discuss the proposed mechanisms as to how RAS interference may delay the onset of T2DM. In particular, as T2DM is characterized by β-cell dysfunction and obesity-related insulin resistance, we address the mechanisms that underlie RAS blockade-induced improvement in β-cell function and insulin sensitivity.
Zijl et al. (Fri,) conducted a review in Type 2 diabetes mellitus in hypertensive high-risk populations. Agents interfering with the renin-angiotensin system (RAS) vs. Other antihypertensive drugs was evaluated on Incidence of type 2 diabetes mellitus (T2DM). Agents interfering with the renin-angiotensin system (RAS) consistently lower the incidence of type 2 diabetes mellitus compared to other antihypertensive drugs in hypertensive high-risk populations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: